Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
We evaluated the cost-effectiveness of combining a cervical cancer screening programme with a national HPV vaccination programme compared to a screening programme alone to prevent cervical dysplasia and cervical cancer related to HPV types 16 and 18 in the Irish healthcare setting. The incremental cost effectiveness of vaccination strategies for 12-year-old females (base-case) and 12-26-year-old catch-up vaccination strategies were examined. The base-case incremental cost-effectiveness ratio was euro17,383/LYG. Using a probabilistic sensitivity analysis about the base-case, the 95% CI for cost per LYG was (euro3400 to euro38,400). This suggests that vaccination against HPV types 16 and 18 would be cost-effective from the perspective of the Irish healthcare payer.
Usher
Cara
C
National Centre for Pharmacoeconomics, St. James's Hospital, Dublin 8, Ireland. cusher@stjames.ie
Tilson
Lesley
L
Olsen
Jens
J
Jepsen
Martin
M
Walsh
Cathal
C
Barry
Michael
M
D000293:Adolescent; D000328:Adult; D002648:Child; D003362:Cost-Benefit Analysis; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000276:immunology*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007494:Ireland / Q000453:epidemiology; D008403:Mass Screening / Q000191:economics; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000191:economics*; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines